Xvivo Perfusion AB (XVIVO) AI Stock Analysis

• Market Cap: $5.28B
• Dividend Yield: N/A
• Average Volume (3M): 187.87K
• Price to Earnings (P/E): 47.4
• Beta (1Y): 1.31
• Revenue Growth: 17.78%
• EPS Growth: -7.83%
• Country: SE
• Employees: 193
• Sector: Healthcare
• Sector Strength: 51
• Industry: Medical - Devices
• EPS (TTM): 0.05
• Shares Outstanding: 31,499,470
• 10 Day Avg. Volume: 213,421
• 30 Day Avg. Volume: 187,872
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): N/A
• P/FCF Ratio: N/A
• Enterprise Value/Market Cap: 1.65
• Enterprise Value/Revenue: 10.59
• Enterprise Value/Gross Profit: 14.14
• Enterprise Value/Ebitda: 101.32
• 1Y Price Target: $195.00
• Price Target Upside: 16.28% Upside
• Rating Consensus: Hold
• Number of Analyst Covering: 0

• Rating: 57 Neutral
• Price Target: kr195.00 ▲(16.28% Upside)

Xvivo Perfusion AB's overall stock score is primarily influenced by its strong financial health, despite challenges in revenue growth and profitability. The technical analysis indicates a bearish trend, and the high P/E ratio suggests overvaluation. The lack of earnings call data and corporate events limits additional insights.

Xvivo Perfusion AB Business Overview & Revenue Model

Company Description

Xvivo Perfusion AB (XVIVO) is a Swedish medical technology company that specializes in organ preservation and perfusion solutions for transplantation. The company focuses on improving the viability of organs for transplant through innovative technologies and products, primarily targeting the fields of lung, kidney, and liver transplantation. XVIVO's core products include organ preservation solutions, perfusion devices, and associated services that enhance the effectiveness of transplant procedures and improve patient outcomes.

How the Company Makes Money

Xvivo Perfusion AB generates revenue primarily through the sale of its organ preservation solutions and perfusion devices to hospitals and transplant centers. The company has established key revenue streams from the direct sales of its products, which are designed to enhance the viability of organs during transport and storage. Additionally, XVIVO may engage in collaborations and partnerships with healthcare institutions and research organizations, providing opportunities for joint ventures and funding. The company also benefits from ongoing service contracts and training programs related to the use of its technologies, further contributing to its financial performance.

Xvivo Perfusion AB Financial Statement Overview

Summary

Xvivo Perfusion AB demonstrates strong financial health with robust gross margins and low leverage. While the company faces challenges with declining revenue growth and net profit margins, it maintains operational efficiency and a solid equity position. Cash flow metrics show improvement, but historical volatility poses a risk.

Income Statement

Xvivo Perfusion AB shows strong gross profit margins consistently above 70%, indicating efficient cost management. However, the TTM (Trailing-Twelve-Months) data reveals a decline in revenue growth rate by 3.75%, which is a concern. The net profit margin has decreased from 20.94% in 2024 to 13.53% in the TTM, reflecting reduced profitability. Despite these challenges, the company maintains a solid EBIT and EBITDA margin, demonstrating operational efficiency.

Balance Sheet

The company maintains a low debt-to-equity ratio of 0.05 in the TTM, indicating low financial leverage and a strong equity position. The return on equity has decreased slightly to 5.29% in the TTM from 7.98% in 2024, but remains positive, showing the company's ability to generate returns on shareholders' investments. The equity ratio remains healthy, reflecting a stable financial structure.

Cash Flow

Xvivo Perfusion AB has shown improvement in free cash flow growth, with a 5.03% increase in the TTM. The operating cash flow to net income ratio is 0.49, indicating moderate cash generation from operations. However, the free cash flow to net income ratio is 1.0, suggesting that all net income is being converted into free cash flow, which is a positive sign. Despite these strengths, the historical volatility in free cash flow remains a concern.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	822.93M	822.41M	597.54M	415.29M	258.39M	179.86M
Gross Profit	616.09M	616.41M	445.11M	296.96M	188.28M	132.97M
EBITDA	85.98M	272.97M	126.57M	39.21M	39.20M	-43.33M
Net Income	111.38M	172.18M	91.82M	18.43M	8.15M	-43.73M
Balance Sheet
Total Assets	2.39B	2.40B	2.20B	1.73B	1.54B	1.15B
Cash, Cash Equivalents and Short-Term Investments	323.00M	415.52M	546.09M	246.54M	398.70M	353.44M
Total Debt	110.81M	34.04M	31.44M	10.01M	5.72M	7.21M
Total Liabilities	295.46M	245.97M	250.57M	302.95M	257.15M	141.85M
Stockholders Equity	2.09B	2.16B	1.95B	1.43B	1.29B	1.01B
Cash Flow
Free Cash Flow	78.51M	-81.86M	-97.65M	-103.09M	-106.13M	-76.94M
Operating Cash Flow	78.51M	111.29M	46.29M	27.86M	-12.06M	-12.27M
Investing Cash Flow	-284.20M	-243.81M	-161.62M	-197.62M	-187.70M	-266.53M
Financing Cash Flow	73.55M	-10.90M	418.55M	-6.84M	234.61M	482.77M

Xvivo Perfusion AB Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 167.70
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Positive
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SE:XVIVO, the sentiment is Negative. The current price of 167.7 is below the 20-day moving average (MA) of 183.09, below the 50-day MA of 221.51, and below the 200-day MA of 351.11, indicating a bearish trend. The MACD of -13.12 indicates Negative momentum. The RSI at 27.07 is Positive, neither overbought nor oversold. The STOCH value of 15.09 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for SE:XVIVO.

Xvivo Perfusion AB Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
XVIVO	57 Neutral	$5.28B	47.43	5.17%	―	17.78%	-7.83%
Sector *	51 Neutral	$7.85B	-0.21	-41.41%	2.22%	22.81%	-2.01%
0GZV	―	kr56.43B	37.99	4.94%	―	―	―
0YAY	―	kr18.50B	41.15	3.46%	5.40%	―	―
CLVSF	―	$439.14M	30.10	18.65%	1.25%	―	―
PXMBF	―	$184.48M	80.83	2.64%	―	―	―
7D2A	―	€132.98M	―	-5.40%	―	―	―

Xvivo Perfusion AB Corporate Events

XVIVO Faces Delay in CE Approval for Heart Perfusion Solution

XVIVO Perfusion AB has announced a delay in the CE approval for its heart perfusion solution, part of its heart preservation technology, due to additional consultation required by EU authorities. Despite this setback, the company’s Heart Assist Transport system has received CE approval, and recent trial results show significant improvements in patient survival, highlighting the technology’s potential impact on heart transplantation.

The most recent analyst rating on (SE:XVIVO) stock is a Sell with a SEK325.00 price target. To see the full list of analyst forecasts on Xvivo Perfusion AB stock, see the SE:XVIVO Stock Forecast page.

XVIVO Initiates US PRESERVE CAP Study for Heart Assist Device

XVIVO Perfusion AB has announced the enrollment of the first patient in the US PRESERVE CAP study for its XVIVO Heart Assist Transport device. This study, approved by the FDA, allows continued clinical use of the device while XVIVO prepares its Pre-Market Approval application. The study’s approval by the Centers for Medicare & Medicaid Services ensures cost recovery, supporting both participating centers and patients. This initiative underscores XVIVO’s commitment to providing life-saving technologies and maintaining continuity of care during the evaluation period.

The most recent analyst rating on (SE:XVIVO) stock is a Sell with a SEK325.00 price target. To see the full list of analyst forecasts on Xvivo Perfusion AB stock, see the SE:XVIVO Stock Forecast page.

Xvivo Perfusion AB Faces Sales Decline Amid Strategic Investments in H1 2025

Xvivo Perfusion AB reported a challenging first half of 2025, with net sales declining by 15% in SEK and 9% in local currencies. The company’s thoracic and services segments experienced negative growth, while the abdominal segment showed a positive sales increase. Despite a stable gross margin, the company faced a significant drop in operating income and net profit, largely due to currency effects and strategic investments in R&D and inventory. These financial results reflect the company’s ongoing efforts to adapt to market conditions and invest in future growth, though they pose challenges for stakeholders in the short term.

The most recent analyst rating on (SE:XVIVO) stock is a Sell with a SEK325.00 price target. To see the full list of analyst forecasts on Xvivo Perfusion AB stock, see the SE:XVIVO Stock Forecast page.

XVIVO Perfusion AB Schedules Conference Call for Q2 2025 Interim Report

XVIVO Perfusion AB announced a conference call to discuss their interim report for April-June 2025, scheduled for July 11, 2025. This event will provide stakeholders with insights into the company’s recent performance and strategic direction, potentially impacting its market positioning and stakeholder interests.

The most recent analyst rating on (SE:XVIVO) stock is a Buy with a SEK460.00 price target. To see the full list of analyst forecasts on Xvivo Perfusion AB stock, see the SE:XVIVO Stock Forecast page.

XVIVO Perfusion AB Wins 2025 SACC-USA Business Award for U.S. Market Growth

XVIVO Perfusion AB has been awarded the 2025 SACC-USA Business Award for its innovative contributions and growth in the U.S. market, particularly in organ perfusion and preservation technologies. This recognition underscores XVIVO’s significant impact on the U.S. healthcare system by addressing the growing demand for organ transplants and highlights the company’s role in strengthening Swedish-American business ties through its life-saving innovations.

The most recent analyst rating on (SE:XVIVO) stock is a Sell with a SEK325.00 price target. To see the full list of analyst forecasts on Xvivo Perfusion AB stock, see the SE:XVIVO Stock Forecast page.